Summary: A new study identifies a previously unrecognized biological pathway in Alzheimer’s disease and reveals a promising therapeutic candidate that slows disease progression. The research shows that the cellular enzyme GRK2 becomes inactivated and aggregates in the brains of people with dementia, damaging mitochondria and driving a self-reinforcing cycle that increases amyloid-beta production and neuronal stress.
To interrupt this destructive loop, researchers developed a targeted molecule called “Compound 10.” This compound prevents GRK2 aggregation, preserves mitochondrial energy production, and markedly delays neuron loss in animal models.
Key Facts
- Long-term tissue research: Foundational work began nearly twenty years ago using post-operative human brain tissue collected at Ain Shams University Hospital in Cairo. Samples came from both patients with dementia and from controls without dementia.
- GRK2 as a regulatory hub: Professor Ursula Quitterer and her team focused on G protein-coupled receptor kinase 2 (GRK2), a regulatory enzyme that helps brain and heart cells respond to stress and external signals.
- Conversion to an inactive form: Molecular analyses of human tissue and mouse models revealed that metabolic changes in Alzheimer’s convert functional GRK2 into an inactive, phosphorylated form that tends to clump together.
- Mitochondrial pore obstruction: Inactive GRK2 aggregates accumulate on mitochondria, blocking their pores, impairing energy production, and causing profound cellular stress.
- Self-perpetuating amyloid-beta loop: Aggregated, inactive GRK2 accelerates amyloid-beta generation. Amyloid-beta then increases cellular stress, driving further GRK2 inactivation and aggregation and creating a vicious cycle that promotes neurodegeneration.
- Compound 10 blocks aggregation: ETH Zurich researchers screened multiple compounds and identified Compound 10 as an effective inhibitor of GRK2 aggregation. In mouse experiments, it improved mitochondrial function, reduced amyloid-beta burden, and extended survival.
- Systemic benefits: Beyond brain effects, Compound 10 improved cardiac function in treated mice and produced systemic anti-ageing signs, such as reduced graying of fur in older animals.
- Extended, age-appropriate studies: Because Alzheimer’s is age related, the team used older mice (about 1.5–2 years), which extended the timeline: individual experiments therefore took up to two years to yield conclusive results. The core research is now complete and a patent application has been filed.
Source: ETH Zurich
“Compound 10” is the name used by Ursula Quitterer for the chemical agent her team developed that shows promise in slowing Alzheimer’s progression.
Quitterer is Professor of Molecular Pharmacology at ETH Zurich. Her team first tested the compound in mice, where results were encouraging: neuronal death characteristic of dementia progressed more slowly and treated animals survived longer than untreated controls.
The new compound traces back to nearly two decades of collaboration. Early tissue samples came from brain tissue removed during tumor surgeries at Ain Shams University Hospital in Cairo, including samples from patients diagnosed with dementia and from patients without dementia.
A new therapeutic target
To understand the mechanism, the researchers studied GRK2 closely. GRK2 is a key regulatory enzyme that modulates how cells react to signals and stress. It is abundant in both the heart and the brain, where it supports neuronal function. Through molecular analysis of human samples and mouse studies, Quitterer’s team clarified the central role that GRK2 dysfunction plays in dementia.
Their findings were published in the journal Cell Reports Medicine.
When a protective protein becomes harmful
GRK2 exists in two states inside cells: an active, functional form and an inactivated form produced by cellular metabolism. The researchers found that the inactivated, phosphorylated form of GRK2 accumulates in the brains of dementia patients and in Alzheimer’s mouse models. This inactive GRK2 assembles into aggregates that attach to mitochondria—the cell’s energy generators—blocking mitochondrial pores and reducing energy output. The resulting energy deficit and intracellular stress compromise neuronal survival.
Experiments in mice also showed that inactive GRK2 enhances production of amyloid-beta, a protein fragment widely implicated in Alzheimer’s disease. Amyloid-beta then increases stress on neurons, which causes more GRK2 to become inactivated and aggregate, perpetuating the pathological cycle.
Breaking the cycle: anti-ageing effects observed
To break this harmful feedback loop, Quitterer’s team synthesized and tested several compounds in cell cultures and animal models. Compound 10 stood out for its ability to prevent GRK2 aggregation. Treated cells and animals showed better mitochondrial function, lower amyloid-beta deposition, preserved neuronal function, and reduced neuronal death.
Beyond the brain, treated mice showed improved heart function and markers consistent with slower biological ageing, including noticeably fewer grey hairs at advanced ages.
Why the research required so much time
The researchers explain that the long timeline reflects the biological reality of studying age-related disease. Accurate modelling of human dementia requires older mice, typically 18–24 months old, and each experiment spans the animals’ ageing window. As a result, each conclusive experimental series can take up to two years, which slows the overall research pace compared with some other fields.
With foundational work complete and a patent filed for Compound 10, Quitterer and ETH Zurich are now seeking industry partners to advance drug development.
“Alzheimer’s is a complex disease,” Quitterer notes. Current treatments do not cure Alzheimer’s and at best delay progression modestly. Identifying GRK2 as a new target—and discovering a compound that works through this distinct mechanism—offers a complementary approach that could, in combination with other therapies, improve patient quality of life.
Key Questions Answered:
A: Through metabolic dysfunction. In dementia, the regulatory enzyme GRK2 becomes inactivated and forms sticky aggregates. These aggregates coat mitochondrial surfaces and block their pores, compromising energy production and leaving neurons starved for the energy needed to survive.
A: Because the process is self-reinforcing: inactivated, aggregated GRK2 increases production of toxic amyloid-beta, which raises cellular stress and causes more GRK2 inactivation and aggregation. Interrupting this loop requires targeting the underlying aggregation process, not only downstream symptoms.
A: Studying age-related diseases follows a biological timeline. To model human dementia faithfully, researchers use older mice (around 18–24 months). Each experimental cycle can take up to two years to produce reproducible, meaningful data, so the entire research program necessarily unfolded over many years.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- The journal paper was reviewed in full.
- Additional context was added by the editorial staff.
About this Alzheimer’s disease and neuropharmacology research news
Author: Marianne Lucien
Source: ETH Zurich
Contact: Marianne Lucien – ETH Zurich
Image: Image credited to Neuroscience News
Original Research: Open access. “Analysis of GRK2 aggregation in the pathology of Alzheimer disease in animal models” by Joshua Abd Alla, Alexander Perhal, Xuebin Fu, Andreas Langer, Yasser el Faramawy, and Ursula Quitterer. DOI: 10.1016/j.xcrm.2026.102707
Abstract
Analysis of GRK2 aggregation in the pathology of Alzheimer disease in animal models
G protein-coupled receptor kinase 2 (GRK2) plays essential roles in cell growth and survival. Investigating a potential connection between GRK2 and Alzheimer’s disease (AD), the study identifies increased aggregated serine-670-phosphorylated GRK2 (phospho-S670-GRK2) in the brains of AD mice and patients with dementia likely due to AD.
Pathogenic phospho-S670-GRK2 aggregation is induced by two hallmark AD proteins: beta-amyloid and TAU-P301L, which promotes neurofibrillary tangles. Aggregated phospho-S670-GRK2 also triggers aggregation of TOMM6 (translocase of outer mitochondrial membrane 6), contributes to mitochondrial dysfunction, and enhances beta-amyloid accumulation. Transgenic expression of inactive GRK2 variants or use of a GRK-inhibitory peptide demonstrate that GRK2 inactivation causes neuropathological features.
Restoring TOMM6 in neurons reduces beta-amyloid plaques but increases soluble beta-amyloid and mortality. In contrast, restoring monomeric GRK2 and promoting proteasomal degradation of phospho-S670-GRK2 with small molecules counteracts neuropathological features of AD, prevents neuronal loss, and improves survival. Targeting pathological GRK2 aggregation therefore slows aging-associated neurodegeneration.